Nephros Inc (NEPH) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Nephros Inc   (NASDAQ: NEPH)


Nephros Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Nephros Inc's ROI in the third quarter of 2026?
Nephros Inc achieved a return on average invested assets (ROI) of 16.11 % in its third quarter of 2026, which is below Nephros Inc's average return on investment, which stands at 176.06%.

Despite the deterioration in its net income, company has improved ROI compared to the second quarter of 2026.

Within the Healthcare sector 40 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 794 to 1143.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 15.32 % 14.2 % 13.05 % 12.69 % 9.14 %
Y / Y Net Income Change TTM 29.03 % 30.82 % -28.81 % 124.44 % 709.29 %
Investment (TTM) in Millions 13 12 11 11 11
Return On Investment (TTM) 16.11 % 15.31 % 7.15 % 11.27 % 14.39 %
NEPH's Overall Ranking # 1143 # 794 # 508 # 538 # 908
Seq. Investment Change TTM 4.67 % 4.51 % 2.38 % 2.98 % 3.66 %
Seq. Net Income Change TTM 10.08 % 123.71 % -35.01 % -19.38 % 11.61 %
Net Income (TTM) in Millions 2 2 1 1 1

NEPH Company Profile >> Back to NEPH Roi Comparisons >> See Annual NEPH Return On Investment



Return On Investment NEPH's Ranking
Within: No.
Industry # 9
Sector # 41
Overall # 1143

Return On Investment Statistics
High Average Low
16283.33 %
176.06 %
-818.09 %
(Dec 31 2013)   (Dec 31 2014)







Financial Statements
Nephros Inc's III. Quarter Investments $ 13 Millions NEPH's Balance sheet
Nephros Inc's III. Quarter Income $ 1 Millions Quarterly NEPH's Income Statement
NEPH's Income by Division See NEPH's Income by Division


NEPH Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 11 10 10 13 18
Y / Y Investment Growth 12.71 % -1.03 % -24.29 % -29.69 % -7.46 %
Net Income in Millions 1 0 -2 -7 -4
Y / Y Net Income Growth 1513.51 % - - - -
Annual Return On Investment 10.98 % 0.77 % -16.16 % -55.19 % -22.43 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 10.98 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NEPH's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NEPH's Competitors
Subscribers only: Roi for Nephros Inc's Suppliers
Subscribers only: Return On Investment for NEPH's Customers

Other Ratios
NEPH's Roa NEPH's Inventory Turnover Ratio NEPH's Growth Rates NEPH's Dividend Statistics
NEPH's Profitability Ratios NEPH's Asset Turnover Ratio NEPH's Dividend Growth
NEPH's Roe NEPH's Valuation Ratios NEPH's Financial Strength Ratios NEPH's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Sanuwave Health Inc   16.50 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %

Date modified: 2026-11-06T12:56:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.